(Q39666645)

13 September 2017

title

Optimization of current and future therapy for autoimmune diseases (English)

1 reference

13 September 2017

Mark Peakman

4

0 references

Iain McInnes

object named as

Iain B McInnes

series ordinal

3

0 references

author name string

Lawrence Steinman

series ordinal

1

1 reference

13 September 2017

Joan T Merrill

series ordinal

2

1 reference

13 September 2017

language of work or name

English

0 references

publication date

6 January 2012

1 reference

13 September 2017

1 reference

13 September 2017

volume

18

1 reference

13 September 2017

issue

1

1 reference

13 September 2017

page(s)

59-65

1 reference

Translating molecular insights in autoimmunity into effective therapy

13 September 2017

cites work

1 reference

Design of effective immunotherapy for human autoimmunity

21 January 2018

1 reference

B-cell-directed therapies for autoimmune disease

21 January 2018

1 reference

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis

21 January 2018

1 reference

IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis

21 January 2018

1 reference

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

Accelerating access to treatments for rare diseases

21 January 2018

1 reference

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential

21 January 2018

1 reference

Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials

21 January 2018

1 reference

TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study

21 January 2018

1 reference

Multiple sclerosis: a complicated picture of autoimmunity.

21 January 2018

1 reference

Immunomodulation by the copolymer glatiramer acetate

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

21 January 2018

1 reference

21 January 2018

1 reference

Mixed results with modulation of TH-17 cells in human autoimmune diseases

21 January 2018

1 reference

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

21 January 2018

1 reference

A molecular trio in relapse and remission in multiple sclerosis

21 January 2018

1 reference

TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.

21 January 2018

1 reference

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

21 January 2018

1 reference

Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis

21 January 2018

1 reference

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

Autoantibody profiling for the study and treatment of autoimmune disease

21 January 2018

1 reference

Autoantigen microarrays for multiplex characterization of autoantibody responses

21 January 2018

1 reference

A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis.

21 January 2018

1 reference

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers

21 January 2018

1 reference

Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production

21 January 2018

1 reference

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease

21 January 2018

1 reference

Inhibitory role for GABA in autoimmune inflammation

21 January 2018

1 reference

Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity.

21 January 2018

1 reference

Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system

21 January 2018

1 reference

Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions

21 January 2018

1 reference

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin

21 January 2018

1 reference

Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus

21 January 2018

1 reference

The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration

21 January 2018

1 reference

Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.

21 January 2018

1 reference

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial

21 January 2018

1 reference

Current and emerging therapies for the treatment of myasthenia gravis

21 January 2018

1 reference

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

21 January 2018

1 reference

Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.

21 January 2018

1 reference

Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays

21 January 2018

1 reference

Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome.

21 January 2018

1 reference

Insulin autoimmunity: prediction/precipitation/prevention type 1A diabetes

21 January 2018

1 reference

Immune intervention in type 1 diabetes.

21 January 2018

1 reference

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

21 January 2018

1 reference

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

21 January 2018

1 reference

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

21 January 2018

1 reference

Inverse vaccination, the opposite of Jenner's concept, for therapy of autoimmunity.

21 January 2018

1 reference

Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites

21 January 2018

1 reference

Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial

21 January 2018

1 reference

Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.

21 January 2018

1 reference

Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes

21 January 2018

1 reference

Antigen-specific immunotherapy of autoimmune and allergic diseases

21 January 2018

1 reference

Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.

21 January 2018

1 reference

Antigen-specific therapies in MS - Current concepts and novel approaches.

21 January 2018

1 reference

Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.

21 January 2018

1 reference

Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression

21 January 2018

1 reference

Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers.

21 January 2018

1 reference

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial

21 January 2018

1 reference

Atorvastatin Fails to Prevent the Development of Autoimmune Diabetes Despite Inhibition of Pathogenic -Cell-Specific CD8 T-Cells

21 January 2018

1 reference

12 December 2020

Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis

1 reference

12 December 2020

The habitual, diverse and surmountable obstacles to human immunology research

1 reference

12 December 2020

1 reference

12 December 2020

Extreme discordant sib pairs for mapping quantitative trait loci in humans

1 reference

12 December 2020

The NIAID Division of AIDS enterprise information system: integrated decision support for global clinical research programs

1 reference

12 December 2020

Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination

1 reference

12 December 2020

Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients

1 reference

12 December 2020

Studies in myasthenia gravis: neonatal and juvenile types

1 reference

12 December 2020

LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus

1 reference

12 December 2020

Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group

1 reference

12 December 2020

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

1 reference

12 December 2020

Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice

1 reference

12 December 2020

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

1 reference

12 December 2020

Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)

1 reference

12 December 2020

The inverse of immunity

1 reference

12 December 2020

Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis

1 reference

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

12 December 2020

Identifiers

DOI

10.1038/NM.2625

1 reference

13 September 2017

1 reference